- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
PLAY BUTTON
PLAY BUTTON
33 Cards in this Set
- Front
- Back
|
phytonadione (vitamin K1)
|
overcomes warfarin inhibiion of hepatic epoxide reductase. given orally or parenterally
|
|
heparin sodium
|
combines w/ antithrombin III and inhibits hemostasis by nonselective inactivation of factors IIa, IXa, Xa, XIa and XIIIa. higher incidence of HIT than LMWH
|
|
protamine
|
inactivates heparin by forming a stable 1:1 complex.
|
|
enoxaparin
|
LMWH: combines w/ antithrombin III and inhibits secondary hemostasis via selective inactivation of factor Xa and IIa(thrombin - less) SQ
|
|
dalteparin
|
LMWH: combines w/ antithrombin III and inhibits secondary hemostasis via selective inactivation of factor Xa and IIa(thrombin - less) SQ
|
|
tinzaparin
|
LMWH: combines w/ antithrombin III and inhibits secondary hemostasis via selective inactivation of factor Xa and IIa(thrombin - less) SQ
|
|
lepirudin
|
direct thrombin inhibitor: binds directly to thrombin and inhibits coagulation. essentially irreversible
|
|
bivalirudin
|
direct thrombin inhibitor: binds directly to thrombin and inhibits coagulation. reversible.
|
|
desirudin
|
direct thrombin inhibitor: binds directly to thrombin and inhibits coagulation
|
|
argatroban
|
direct thrombin inhibitor: binds directly to thrombin (active site ONLY) and inhibits coagulation. reversible
|
|
dabigatran
|
direct thrombin inhibitor: binds directly to thrombin and inhibits coagulation. only oral direct thrombin inhibitor. reversible
|
|
drotecogin alfa/ recombinant activated protein C
|
proteolytically inactivates factors Va and VIIIa. WITHDRAWN FROM MARKET
|
|
fondaparinux
|
indirect factor Xa inhibitor: combines w/ antithrombin III and inhibits hemostasis via highly selective inactivation of factor Xa. no monitoring.
|
|
rivaroxaban
|
direct factor Xa inhibitor: combines directly w/ free and clot bound factor Xa. oral. high bioavailability
|
|
apixaban
|
direct factor Xa inhibitor: combines directly w/ free and clot bound factor Xa. IN TRIALS STILL. oral.
|
|
warfarin
|
vitamin K antagonist: inhibits hepatic epoxide reductase required for synthesis of biologically active coag factors II, VII, IX, X and anticoagulant proteins C and S. oral. requires monitoring. avoid in pregnancy
|
|
streptokinase
|
proteolytically activates plasminogen to form plasmin which digests fibrin to fibrin degradation products. can cause allergic reactions and doesn't bind fibrin.
|
|
alteplase
|
proteolytically activates plasminogen to form plasmin which digests fibrin to fibrin degradation products.
|
|
reteplase
|
proteolytically activates plasminogen to form plasmin which digests fibrin to fibrin degradation products. longer halflife than alteplase
|
|
tenecteplase
|
proteolytically activates plasminogen to form plasmin which digests fibrin to fibrin degradation products. higher affinity and longer halflife than alteplase
|
|
aminocaproic acid
|
lysine analog: binds and inhibits plasminogen and plasmin.
|
|
tranexamic acid
|
lysine analog: binds and inhibits plasminogen and plasmin
|
|
aprotinin
|
serine protease inhibitor: inhibits serine proteases including plasmin, t-PA, and thrombin. WITHDRAWN FROM THE MARKET.
|
|
aspirin
|
COX inhibitor: inhibits platelet cyclooxygenase blocking thromboxane A2 production
|
|
dipyridamole
|
cAMP elevating agent: inhibits reuptake of adenosine leading to A2 receptor mediated stimulation of adenylate cyclase.
|
|
cilostazol
|
cAMP elevating agent: inhibts cAMP phosphodiesterase (PDE III) used for intermittent claudication. contraindicated in heart failure. reversible inhibition
|
|
ticlodipine
|
covalently modifies platelet ADP receptor (2PY12 inhibitor) oral agents
|
|
clopidogrel
|
covalently modifies platelet ADP receptor (2PY12 inhibitor) oral agents. favored over ticlodipine
|
|
prasugrel
|
covalently modifies platelet ADP receptor (2PY12 inhibitor) oral agents. more potent than clopidogrel
|
|
ticagrelor
|
covalently modifies platelet ADP receptor (2PY12 inhibitor) oral agents
|
|
tirofiban
|
GP IIb/IIIa inhibitor: binds to platelet receptor GP IIB/IIIa and prevents binding of fibrinogen and other adhesive ligands. nonpeptide tyrosine analog
|
|
abciximab
|
GP IIb/IIIa inhibitor: binds to platelet receptor GP IIB/IIIa and prevents binding of fibrinogen and other adhesive ligands. chimeric Fab fragment
|
|
eptifibatide
|
GP IIb/IIIa inhibitor: binds to platelet receptor GP IIB/IIIa and prevents binding of fibrinogen and other adhesive ligands. cyclic peptide.
|
